Global Acute Lymphocytic or Lymphoblastic Leukaemia (ALL) Therapeutics Market is estimated to value over USD 3.4 billion by 2026 end and register a CAGR of over 5% during the forecast period 2019 to 2026.
Increase in initiatives undertaken by private and public organizations and growing incidence of Acute Lymphoblastic Leukaemia (ALL) are some of the key factors expected to drive acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market growth.
Advancements in technology made for detecting affected cells are considered as one of the drivers for Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market growth. For example, Novartis AG’s Chimeric Antigen Receptor T-cell therapy is an innovative therapy.
Many nongovernment and government organizations, such as the National Institutes of Health, the National Cancer Institute (NCI), the American Cancer Society and the Foundation for the, have arranged diagnostic campaigns and undertaken initiatives for detection of ALL.
Moreover, the “Therapeutically Applicable Research to Generate Effective Treatments (TARGET)” initiative with collaboration with many research groups and launched multiple programs across different countries such as the University of New Mexico and St. Jude Children’s Research Hospital etc., to provide facilities to patients for better treatment and early diagnosis of Leukaemia.
ALL treatment consists of different therapies such as targeted therapy, chemotherapy, stem cell transplant and radiation therapy. Chemotherapy segment led the market in 2016 due to factors like its ability to prevent thriving & multiplication of cancerous cells and destroy Leukaemia cells that restrain the progress of the disease. All these factors are responsible for the increase in the rate of prescription of chemotherapy for the last decade, thus expanding the acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market size. In chemotherapy, single or combination drugs are used for treating ALL. This therapy includes antimetabolites, alkylating agents, cytotoxic agents, and other plant derivatives. Additionally, stem cell transplant can be used together with chemotherapy, which helps healthcare practitioners instigate chemotherapy infusions at high doses for effective treatment.
ALL is categorised into three types- precursor B-ALL, Philadelphia (Ph) chromosome and T-cell ALL. The Philadelphia (Ph) chromosome is further bifurcated into Ph-negative ALL and Ph-positive ALL. The chances of acquiring this disease increase with age. The drugs used for the treatment of ALL are usually tyrosine kinase inhibitors like imatinib (Glivec), dasatinib (Sprycel), , and nilotinib (Tasigna). The aforementioned drugs have many indications with acute lymphoblastic leukaemia as one of them.
Key market players include Erytech Pharma, Spectrum Pharmaceuticals Inc., Bristol-Myers Squibb Company, Genzyme Corp. (Sanofi), Pfizer Inc., Sigma-tau spa, Novartis AG, Celegene Corp., Juno Therapeutics Inc.
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=3399&...
Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Segmentation:
By Product
• Chemotherapy
o Hyper-CVAD
o CALGB 8811 Regimen
o Linker Regimen
o Nucleoside Metabolic Inhibitors
o Oncaspar
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation
By Type
• Philadelphia Chromosome
o Positive Ph (Ph+)
o Negative Ph (Ph-)
• Precursor B-Cell ALL
• T-Cell ALL
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=3399&...
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global acute lymphocytic/lymphoblastic Leukaemia (ALL) therapeutics market by product, by type and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region-wise market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Acute lymphocytic/lymphoblastic leukemia therapeutics market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising incidences of acute lymphoblastic leukemia
3.2.2 Technological advancements
3.2.3 Increasing initiatives from public and private organizations
3.2.4 Increasing preference over targeted therapies
3.3 Market Restraint Analysis
3.3.1 Regulatory issues and patent expiry of blockbuster drugs
3.4 Penetration & growth prospect mapping
3.5 Acute lymphoblastic leukemia therapeutic market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
3.7 Company Market Share, 2016
Chapter 4 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product Estimates & Trend Analysis
4.1 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market, 2014 - 2026 (USD Million)
4.2.2 Hyper-CVAD
4.2.2.1 Hyper-CVAD market, 2014 - 2026 (USD Million)
4.2.3 CALGB 8811 regimen
4.2.3.1 CALGB 8811 regimen market, 2014 - 2026 (USD Million)
4.2.4 Linker regimen
4.2.4.1 Linker regimen market, 2014 - 2026 (USD Million)
4.2.5 Nucleoside Metabolic Inhibitors
4.2.5.1 Nucleoside Metabolic Inhibitors market, 2014 - 2026 (USD Million)
4.2.6 Oncaspar
4.2.6.1 Oncaspar market, 2014 - 2026 (USD Million)
4.3 Targeted Therapy
4.3.1 Targeted therapy market, 2014 - 2026 (USD Million)
4.4 Radiation Therapy
4.4.1 Radiation therapy market, 2014 - 2026 (USD Million)
4.5 Stem cell transplantation
4.5.1 Stem cell transplantation market, 2014 - 2026 (USD Million)

Chapter 5 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Type Estimates & Trend Analysis
5.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Type Movement Analysis
5.2 Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
5.2.1 Philadelphia chromosome market, 2014 - 2026 (USD Million)
5.3 Precursor B-cell ALL
5.3.1 Precursor B-cell ALL market, 2014 - 2026 (USD Million)
5.4 T-cell ALL
5.4.1 T-cell ALL market, 2014 - 2026 (USD Million)

Chapter 6 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Regional Estimates & Trend Analysis, by Product
6.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market share by region, 2016 & 2026
6.2 North America
6.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.2.2 U.S.
6.2.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.2.3 Canada
6.2.3.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.3 Europe
6.3.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.3.2 UK
6.3.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.3.3 Germany
6.3.3.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.3.4 France
6.3.4.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.4 Asia Pacific
6.4.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.4.2 Japan
6.4.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.4.3 China
6.4.3.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.4.4 India
6.4.4.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.5 Latin America
6.5.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.5.2 Brazil
6.5.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.5.3 Mexico
6.5.3.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.6 MEA
6.6.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)
6.6.2 South Africa
6.6.2.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2026 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Erytech Pharma.
7.3.1.1 Company overview
7.3.1.2 Financial Performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Spectrum Pharmaceuticals Inc.
7.3.2.1 Company overview
7.3.2.2 Financial Performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Genmab A/S
7.3.3.1 Company overview
7.3.3.2 Financial Performances
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Bristol-Myers Squibb Company
7.3.4.1 Company overview
7.3.4.2 Financial Performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Genzyme Corporation (Sanofi)
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Pfizer, Inc.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Sigma-tau spa
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Novartis AG
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Celgene Corporation
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 Juno Therapeutics, Inc.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives

Chapter 8 Research Finding and Conclusion
Chapter 9 Research Methodology
Chapter 10 Research DataSource

Inquire further details about this report at: [email protected]

About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.

Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com